Rechercher un essai clinique
Autre(s) option(s) de recherche
11 Résultat(s)
Essai en cours de recrutement = 
; Essai en cours = 
; Essai terminé = 
; Financé par un membre IRDiRC = 
; Membre d'un ERN = 
Essai(s) clinique(s) national(aux)
ALLEMAGNE
Baden-Württemberg
FREIBURG
SIPA-SOS: An open label phase II study of Sirolismus in patients with segmental overgrowth syndrome
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Pädiatrische Hämatologie und Onkologie
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations - AT
Institution: Information not provided - AT
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VASE: Etude multicentrique de phase III visant à évaluer l'efficacité et la sécurité d'emploi du sirolimus dans le traitement des malformations vasculaires réfractaires aux soins standards - BE
Cliniques universitaires Saint-Luc - UCLouvain
Centre des Malformations Vasculaires
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
A Randomized Double-Blind Controlled Trial of Everolimus in Children and Adolescents With PTEN Mutations (RAD001XUS257T)
Institution: Information not provided - US
FRANCE
NORMANDIE
CAEN
PAYS-BAS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Programme d'extension à long terme du Sorafénib - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
ITALIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma - IT
Institution: Information not provided - IT
ITALIE
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
Essai(s) clinique(s) multinational(aux)
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS